Novo Nordisk's shares dropped 6.7% in Denmark after the company's Wegovy weight-loss drug missed sales expectations as a result of the bigger discounts offered to U.S. buyers.

Novo Nordisk’s shares dropped 6.7% in Denmark after the company’s Wegovy weight-loss drug missed sales expectations as a result of the bigger discounts offered to U.S. buyers.